Journal Pre-proof Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2- yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors Vagolu Siva Krishna, Shan Zheng, Estharla Madhu Rekha, Radhika Nallangi, D.V. Sai Prasad, Shilpa E. George, Luke W. Guddat, Dharmarajan Sriram PII: S0223-5234(20)30145-8 DOI: https://doi.org/10.1016/j.ejmech.2020.112178 Reference: EJMECH 112178 To appear in: European Journal of Medicinal Chemistry Received Date: 22 April 2019 Revised Date: 12 February 2020 Accepted Date: 20 February 2020 Please cite this article as: V.S. Krishna, S. Zheng, E.M. Rekha, R. Nallangi, D.V. Sai Prasad, S.E. George, L.W. Guddat, D. Sriram, Design and development of ((4-methoxyphenyl)carbamoyl) (5- (5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol- acid reductoisomerase inhibitors, European Journal of Medicinal Chemistry (2020), doi: https:// doi.org/10.1016/j.ejmech.2020.112178. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier Masson SAS.